Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Everolimus (Afinitor®)	TA432 - Everolimus for advanced renal cell carcinoma after previous treatment TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease TA421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy	Negative outcome - CDF funded for renal, NET, breast. For hospital use only.
Evolocumab	TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia & Homozygous familial hypercholesterola EMIA in line with NHS England SSC 1649	To be used in line with NICE TA
Exemestane tablets	TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Exenatide prolonged release injection (Bydureon®)	NICE NG28: Type 2 diabetes in adults - management
Ezetimibe tablets	TA132 - Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
Febuxostat tablets	TA164 - Febuxostat for the management of hyperuricaemia in people with gout
Fedratinib (Inrebic®)	TA756 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
Fenfluramine	TA808 - Fenfluramine for treating seizures associated with Dravet syndrome
Ferric maltol (Feraccru®)	RICaD for Ferric maltol (pdf)	For the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD), unable to tolerate other oral iron formulations. Supported by a RICaD
Filgotinib (Jyseleca®)	TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.